Part 1| ADNeT Screening and Trials Protocol: Measures and Interpretation

During the first part of the webinar, Dr Robertson will provide an overview of the measures administered by ADNeT, together with notes on their interpretation. ADNeT's Screening and Trials program recruits interested subjects for the purpose of assessing their suitability for further participation in research and clinical trials. To this end, a number of cognitive and mood measures are administered as part of the ADNeT Screening battery to inform eligibility.

Part 2 | Interpretation of Amyloid PET Reports

Amyloid PET is an accurate test for the detection of amyloid beta (Aβ) plaques demonstrating more than 90% concurrence with a post-mortem classification of moderate or frequent Aβ plaque deposition. Importantly, neuropathological criteria also require the presence of tau neurofibrillary tangles to confirm a neuropathological diagnosis of Alzheimer’s disease (AD). However even then, individuals who meet neuropathological criteria for AD may be cognitively intact. In Part 2 of this webinar, Prof. Rowe will discuss through case-based learning the clinical implications of a positive and negative Amyloid PET scan. His presentation will also highlight the importance of considering the level of brain amyloid present on the scan, the age and clinical status of the patient as well as the likelihood of co-existent other brain pathology when deciding if AD is the predominant cause of cognitive impairment in an individual.

Websites/resources provided in this Webinar:

[ Ссылка ] - The Australian Dementia Network Website

[ Ссылка ] - ADNeT Neuropsychological Norming Tool (Registration Form)

[ Ссылка ] - The Australian Dementia Network’s National Memory and Cognition Clinic Guidelines

[ Ссылка ] - Find a Memory Clinic or Cognitive Decline Assessment Service

Webinar chapters:

00:00 Introduction
03:06 Dr Jo Robertson’s Presentation
18:15 Prof Christopher Rowe’s Presentation
53:27 Q&A

свернуть